Sirolimus, also known as rapamycin, is listed as a 1 mg product. Its literature crosses laboratory biology, clinical treatment and aging-related research.
50,873records matching the ingredient search
1connected formulations
8displayed publication records
How the research connects to the formula
The ingredient-name query includes both names. The publication chart therefore describes that full search, including subjects beyond longevity. A source’s species, regimen and endpoint decide which research question it answers.
Aging research can use a biochemical marker, a functional measure or survival as an outcome. Those endpoints should be recorded separately, with the study population or species beside them.
The chart counts records mentioning the search terms in their title or abstract. It includes research beyond longevity. Use the period controls to inspect the count.
2026: 1,973 indexed publications. 2026 includes publications dated through October 5. The earlier bars cover longer periods than the annual bars.
View the chart as a data table
Period
Publications
1900-1959
0
1960-1969
0
1970-1979
5
1980-1989
6
1990-1999
1366
2000-2009
8777
2010-2014
10432
2015-2019
12904
2020
2787
2021
2784
2022
2582
2023
2428
2024
2330
2025
2499
2026
1973
Search query and data source
Source: Europe PMC’s PubMed-indexed records. Retrieved October 5, 2026. The index’s firstPublicationDate field supplies the dates and chart periods; it can normalize a month-only record to the first day of the month. Dates through October 5 are included. Counts can change as the index adds or corrects records.
TITLE_ABS:((sirolimus OR rapamycin)) AND SRC:MED AND FIRST_PDATE:[1900-01-01 TO 2026-10-05]
The focused search returns 26 publications. It narrows the ingredient query to terms connected with its catalog use. Its displayed records remain a search sample, not a ranking of study quality.
View the focused query
TITLE_ABS:((sirolimus OR rapamycin)) AND TITLE_ABS:((aging AND randomized)) AND SRC:MED AND FIRST_PDATE:[1900-01-01 TO 2026-10-05]
The timeline combines selected references with a sample from the ingredient search. Dates use the index’s firstPublicationDate field; the PubMed record may distinguish an earlier online date from the print date. Written study notes appear alongside the records that have them. Other entries show the indexed bibliography and link to the paper.
A single-center, double-blind, randomized, placebo-controlled, two-arm study to evaluate the safety and efficacy of once-weekly sirolimus (rapamycin) on muscle strength and endurance in older adults following a 13-week exercise program.
Stanfield B, Kaeberlein M, Leroux B, Jones J, Lucas R, Arroll B. Trials. PMID 39354527.
This record identifies a publication and its indexed publication types. The full paper contains the study methods, population, formulation and results.
Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project.Coleman AE, Creevy KE, Anderson R, Reed MJ, Fajt VR, Aicher KM, Atiee G, Barnett BG, Baumwart RD, Boudreau B, Cunningham SM, Dunbar MD, Ditzler B, Ferguson AM, Forsyth KK, Gambino AN, Gordon SG, Hammond HK, Holland SN, Iannaccone MK, Illing K, Kadotani S, Knowles SA, MacLean EL, Maran BA, Markovic LE, McGrath S, Melvin RL, Mueller MS, Nelson OL, Olby NJ, Pancotto TE, Parsley E, Potter BM, Prescott JO, Saunders AB, Sawyer HM, Scansen BA, Schmid SM, Smith CC, Tjostheim SS, Tolbert MK, Tropf MA, Visser LC, Ward JL, Wesselowski SR, Windsor RC, Yang VK, Ruple A, Promislow DEL, Kaeberlein M, Dog Aging Project Consortium.GeroScience. 2025-02-14. PMID 39951177. Clinical Trial Protocol, Research Support, Non-U.S. Gov't, review-article, Journal Article, Research Support, N.I.H., Extramural.
Research data assembled by HealthRX.com from the displayed source records, October 5, 2026. The atlas contains a dated literature search and selected studies; it is not an exhaustive systematic review.